Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.6001
-0.0573 (-8.72%)
Nov 16, 2026, 3:39 PM EST - Market open
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Commercial launches are underway, with Flora Sync on market and DARE to PLAY 503B dispensing expected later in 2026. Ovaprene and DARE-HPV data are expected in 2027, supported by grant funding.

Operator

Good morning, everyone, and welcome to the Daré Bioscience session. We have Sabrina Johnson, CEO, with us today to talk about Daré, which is a diversified, partner-based women's health company, which is a rarefied breed these days. Sabrina, why don't you come up and give us the-

Sabrina Johnson
CEO, Daré Bioscience

Awesome.

Operator

-story, and then we'll go into questions.

Sabrina Johnson
CEO, Daré Bioscience

Perfect. Hello, hello. Thank you all for being here today. Definitely look forward to going over where we are. It's an exciting time for the company. We are publicly traded. For the looking disclaimers, please do look at our risk factors and our SEC filings for most current update. As was just shared, we're really focused on women's health, and what does that mean? I really think of us as a biotech company that is purpose-driven in its focus on closing the gap between promising science and real-world solutions for women. In terms of what that means from an investment perspective, sorry, I'm going back and forth.

What that means from an investment perspective is that sole focus is we're focusing on where the white space exists in women's health, which is actually a lot across the continuum from contraception through menopause, because it's been an area that has been under-researched and understudied, and so a lot of opportunities exist, and that's where we're really leaning in. I really think of our strategy as four pillars. One, we're at a transition point. We're moving into directly commercializing some of our products, so I'm definitely going to focus on that today, and 2026, as we're going into 2027, is the time to watch for that. What we share across the portfolio is offering clinically evidence-based solutions.

That might sound like a no-brainer when you are at a conference like this and you are looking at what the field is in other healthcare areas, but that is actually a unique feature in the women's health landscape in terms of the products that we are offering, where we are matching that unmet need to a solution that is actually fit for purpose and designed for it. There is a pipeline behind the commercial programs that we are launching right now, which is also unique in this category.

The fourth thing that I would highlight that we will talk about a little bit more is because this has been such an underfunded and under-researched area, there is a significant amount of non-dilutive capital available, including for our late-stage programs, phase II and phase III. That really supports that pipeline moving forward. When I say we focus on women's health, what does that mean?

We are not a company around one product, and we are not a company around one life stage, one condition. We are really across that continuum. Where we focus is where are there the biggest therapeutic gaps that exist today, where there is proof of concept science that can really clearly address that gap. We focus on primarily products that are already FDA approved for another indication or another dosage form that is not ideally fit for purpose for the indication in question. As you can see from this, we really work from contraception through to menopause and everything in between, infectious disease, vaginal health, maternal health, fertility.

In terms of the really kind of six programs in particular that I would ask you to focus on right now, and we will highlight them as we go through the presentation, the top two, Flora Sync LF5 and DARE to PLAY Sildenafil Cream, are the two that are either live now on market, that is Flora Sync, our vaginal probiotic, or soon to be live on market, and that is DARE to PLAY Sildenafil Cream. So I am definitely going to highlight those a bit more for you.

But there is also products that I think make sense watching right now because of milestones that are going to hit next year. Two of those are development stage products, a potential first treatment for human papillomavirus infection, which causes cervical cancer, that has a phase II readout next year, and Ovaprene, our once-a-month hormone-free contraceptive, which has a phase III readout next year.

DARE to RECLAIM, we also call it DARE-HRT1, is our menopause hormone therapy. Menopause is definitely having a moment. We will talk about that a little bit. We are proud to be bringing forward, hopefully to market next year, a product that has the potential to be the first once-a-month hormone therapy product with estradiol and progesterone together that really fits kind of the recommendations of The Menopause Society guidelines for hormone therapy, which is non-oral and both of those hormones together. That same ring technology we utilize to deliver progesterone, which is used in IVF, and could be a potential treatment for preterm birth. We are looking forward to getting that vaginal ring into an NIH-funded phase I study. Let us talk about why women's health and why these products.

Also as an aside, I noticed that the clock's not moving, so I don't have a good sense of-

Operator

Please start the clock.

Sabrina Johnson
CEO, Daré Bioscience

-my time, but I'll keep an eye on it. Why women's health and why now? First of all, the why now. It should have been why always. But why now? It's definitely having a moment. You can't help but look at anything on social media. You'd have to be kind of living in a hole somewhere to not sort of hear the noise around women's health right now, whether it's menopause, fertility, IVF. It's really across a wide variety of sectors. We find the category so interesting, like I said, for really kind of three key reasons. One, I want to state this upfront. I think it's pretty obvious with the GLP-1s, we're seeing it, but women are very motivated healthcare consumers. They make the vast majority of the healthcare decisions for their households and also themselves.

I think GLP-1s are a great example of what happens when there's a product that works well, delivers, is kind of fit for purpose for what it's doing, and can serve that unmet need in a women's category. The markets, the other thing we like so much, is that the markets are so large, right? When we think about a number of the things that we work in in women's health, these are not diseases the way you might traditionally think of a disease. Menopause is not a disease, right? Changes even in sexual health, it's not a disease per se. It's just shifts in hormones and other factors that can change how someone responds. Contraception, right? Family planning is not a disease. What that means is that they tend to be very large populations.

They're things that every woman or almost every woman is going to experience or need to think about at some point in their lifetime. That also means that form factor matters, right? Is it convenient to use? Does it really fit her lifestyle? Those are the kind of gaps that we're looking to fill. Because it's been such an under-researched category, there are areas like human papillomavirus that everyone acknowledges is the virus behind causing cervical cancer. It's one of the few cancers that we actually know is what causes it, but yet it's the only sexually transmitted infection where we don't have a treatment that exists today, when someone tests positive for that virus. So those are the kind of opportunities and the kind of white space that we're looking to fill.

The third reason I highlighted up front that we find this from an investor perspective is really a category to look at and us as a company to look at, is there a significant non-dilutive funding that's available? It's really filling that gap that's existed because women were not required to be in clinical research until 1993. Because of that gap that is widely recognized, you've got foundations like the Gates Foundation, but also ARPA-H, government agencies, NIH, that are investing significantly to ensure that truly differentiated products that address these gaps have the ability to move forward. We have been incredibly fortunate in bringing in over $75 million in this non-dilutive funding to support our portfolio.

The other thing that we're seeing right now, and again, I'm going to point kind of to the GLP-1 categories and other categories where we're seeing it, there's a lot of compounding happening. That happens when people are trying to fill a void, right? A market need that exists. What is, again, unique about the offerings that we have, regardless of how we go to market, whether it's as a non-prescription product, and we're going to talk about DARE to PLAY Sildenafil Cream, where we're starting as a 503B compounded product, is we have the clinical data and the evidence behind it. So it's a fantastic way to fill a market gap with a market solution, but that has that data behind it so that patients and healthcare providers can rely on that information.

It also means that we can really take advantage of where the market is shifting in terms of commercial platforms and online platforms. Telehealth that we offer ourselves, but also partnering with other telehealth providers and other online solutions for patients. Let's talk real quick about the commercial products first. Flora Sync launched earlier this year, this summer. It is a vaginal probiotic. So the vagina, just like the gut, has a microbiome, and similarly, it can be disrupted, and really important for it to be balanced. Maybe a little dissimilar to the gut microbiome, it's really obvious to women when the vaginal microbiome is disrupted because she will notice changes that are happening.

Flora Sync is one of the only, if not the only, vaginally delivered probiotic that's just a three-course, meaning three days, once a day for three days, capsule that's designed to restore that microbiome, and that has been demonstrated and clinically studied in a randomized controlled trial that has been published to demonstrate that it restores that in 96% of patients, and that most of them, 90%, maintain it two weeks out. We just made this available. It's really because of the clinical data behind it. It's a product that we can think about promotion the same way you might with a prescription product in that we're heavily sampling to healthcare providers, supporting healthcare providers who want to sell this directly in their clinic, as well as it being available online. Sildenafil Cream, this is, most people know sildenafil.

It's the same active ingredient that is in the well-known erectile dysfunction drug, Viagra. Women, like men, can benefit from having increased blood flow. That's what's behind the female physical arousal response. This formulation is a proprietary formulation of sildenafil that was really designed and clinically demonstrated to increase blood flow in women very quickly, within 10- 15 minutes of application, and demonstrated to improve those physical arousal sensations, those pleasurable sensations that also comes from that increased blood flow. It is the only clinically studied formulation of Sildenafil Cream that is available. We are continuing to work towards advancing it to an FDA approval, but based on clinician demand, we are making it available as a 503B compounded product, and that should start dispensing later this year. We've already started taking in prescriptions. What is 503B compounding? Basically, it's not at a pharmacy.

It's not on a named patient basis. It means that that manufacturer, which is an outsourcing facility, has to meet the same quality standards that the FDA uses for traditional FDA-approved pharmaceutical products in terms of GMP manufacturing, subject to FDA inspection, and subject to FDA reporting. That will be available later this year. Excited to talk more about that. How are we commercializing these products? How are we promoting them? Because we are so uniquely suited and uniquely a player in the women's health space in terms of being the only company working broadly on therapeutics in women's health. We have longstanding relationships across the healthcare continuum that we're really able to leverage in what I kind of think of as peer-to-peer communication, education around our products.

We are able to have healthcare providers sell our products in their offices, educate other clinicians about our products, and obviously, they're supported through all the clinical research. We're really able to turn that into a commercial advantage in terms of both awareness, opportunities to accelerate how we're getting these products to market, and that really also then helps our development programs, right, by expanding that provider relationship. How we think about the commercialization is really leaning into digital and a digital platform. The products are all available on our Daré Health Hub, which I'll show in a second. Whether a provider is going there, someone is going there directly through telehealth, they're learning about it through Instagram, through TikTok, through our influencer programs, they're landing at the same page on the front end and on the back end.

That really allows us to have this integrated solution both for communicating about our products, but also gathering the information about our prescribers and the customers that are using our products. It's the DARE Health Hub. It's obviously live right now. You can get a prescription for DARE to PLAY today. You can order Flora Sync LF5 on that hub, and that also allows us, as we continue to add products, for cross-selling there as well, which is great. I talked about really leaning into digital. That also means we're really leaning into really a social media strategy. It is where women, many women are getting their information about solutions that they want to try and problems that they're trying to solve. We obviously want to do that.

We're really committed to credible science and credible information, and there's a real opportunity for that through clinician influencers, whether they're sex educators, whether they're clinicians, like gynecologists that have podcasts. You'll be seeing a lot more of that. We started doing those earlier this year, and you're going to be seeing more and more and more of that across a variety of channels. I'm going to quickly go through the development pipeline because one of the beauties around Daré as a company is that we've got these to-market or near-to-market products, but we have an exciting, similarly first-in-category portfolio of development stage candidates right behind it. The first one I want to talk about is Ovaprene, because that's in phase III right now. It is a once-a-month hormone-free contraceptive. It is the only product of its kind in that category.

It is in its registration trial right now. We've had two positive data safety monitoring board meetings. They're focused on safety, but obviously, pregnancy is a safety event, so they do get a sense of what women are experiencing on the product. The study data so far continue to support what was projected for this product based on the phase II, which is an 86%-91% typical use effectiveness rate. To put that in perspective, that's higher than condoms, that's higher than spermicides, so the other short-acting methods in the category, pretty similar to diaphragms, and just under what a hormonal method would be. We are expecting to complete enrollment this year and to have phase III data next year on this product. The other exciting readout we have coming up next year is our human papillomavirus infection product. It's in phase II right now.

That's completely funded by ARPA-H. I should have mentioned the Ovaprene study was supported by the NIH and the Gates Foundation. DARE-HPV is supported with a grant from ARPA-H that supports that phase II trial. It's a combination antiviral. It's two protease inhibitors that have been used in the HIV space, lopinavir and ritonavir, but in a fixed-dose combination that has been really optimized for vaginal delivery. So, we're delivering those antivirals right where they need to be to get the response. This could be a real game-changer. Right now, women just live with the infection, knowing that they may get cervical lesions or cervical cancer down the road without any means of eradicating the infection when they find out that they have it. So, data on this one coming next year. Then just a couple other I want to highlight.

I mentioned up front our menopause hormone therapy vaginal ring. We are pursuing a similar strategy with this one, like we did with DARE to PLAY, the DNF0 cream, where we launch it as a 503B while we're continuing in process to support the registration. The phase I/II data that already exist already demonstrated that this ring gets women to a pre-menopause level of estradiol and a protective level of progesterone in one once-a-month product. We are very excited to get this to market to women. We also have a non-hormonal approach for women, specifically experiencing sexual pain. This could be a big issue in a breast cancer survivor population, where the drugs they're on for their hormone receptor-positive breast cancer puts them in a very rapid and often early menopause-like condition, but often hormones are avoided in this population. This is a non-hormonal vaginal approach.

It's cleared to go into phase II, and we are working on preparing for that. Then I mentioned that same ring technology that we use for menopause hormone therapy, we can also use it to deliver progesterone alone. This one we're looking at as an alternative to those painful injections in IVF of progesterone as well as for preterm birth, and it's supported by a grant from the NIH to support the phase I. I'm not going to mention the preclinical programs other than say there's a whole other portfolio behind that, either in phase I or preclinical. Similarly, all grant funded, so all of the earlier stage programs are supported with grants. I'm going to skip the financial snapshot, just catch up with us soon on our earnings call for more up-to-date information.

Obviously, highly experienced management team, not only in women's health, but broadly on bringing really novel products to market. Then I'll leave you with a couple slides just really on our near-term catalysts. Like I said, it's a fantastic time if you're just getting to know us for the first time, because we got these commercial milestones happening now, real time, and then we've got those really two important data readouts next year, and hopefully another commercial milestone next year as well with our menopause product. I'll leave this slide up, and happy to take I know Annabelle has some questions. Happy to sit down and take questions, and I'll leave you with this slide while we do that.

Operator

Okay, so that was a mouthful.

Sabrina Johnson
CEO, Daré Bioscience

I know. That was my super quick-

Operator

Your pipeline.

Sabrina Johnson
CEO, Daré Bioscience

-lots to know.

Operator

Your pipeline has definitely expanded a lot more than from the last time that-

Sabrina Johnson
CEO, Daré Bioscience

Yeah.

Operator

-we saw each other.

Sabrina Johnson
CEO, Daré Bioscience

Yes.

Operator

But maybe we can talk a little bit bigger picture. I know there's been a tremendous effort to bring attention back to women's health. There's large women's initiatives.

Sabrina Johnson
CEO, Daré Bioscience

Yes.

Operator

There's work in Washington, there's work at independent-

Sabrina Johnson
CEO, Daré Bioscience

Yep.

Operator

-institutions. Can you talk about any kind of policy changes that have helped bring that attention back and helped with your funding, frankly?

Sabrina Johnson
CEO, Daré Bioscience

Absolutely. There's a lot going on right now, and I look at Daré, we started, I started the company 11 years ago, so we were ahead of our time, but that makes us prepared for where the moment is today.

Operator

It's amazing.

Sabrina Johnson
CEO, Daré Bioscience

I feel.

Operator

That you can say ahead of our time. Women have existed this whole time.

Sabrina Johnson
CEO, Daré Bioscience

I know, but I look at the moment we're in right now, we are so uniquely positioned. I feel like there's finally fuel getting poured on the fire, and we're right there to get the fuel, which is, there is a lot happening at all levels, both at institutions and at the government level. Let's start first with the government. There are very few things that the past administration and the current administration agree on, but you know what they both had in common? They both did executive orders around women's health and increasing investment in women's health. It speaks to the fact that there is a gap, there's a recognized gap in investment and translation of what we're doing, translating really interesting science into products that get into the hands of women.

You're seeing it at the highest levels in terms of an effort to get this forward. We've seen FDA actions that were taken recently. They removed last year, at the end of last year, they removed, and I should have mentioned this in the presentation, but they removed the black boxed warning on hormone therapy products that frankly scared many women and the market away from really appreciating the opportunity there. That's a category that compounded is a $2 billion-$4 billion category. Now with the black boxed warning removed, that category is ripe for movement. That's the FDA. FDA just held earlier this year a public meeting on how do we get a testosterone approved for women? Who would have thought?

I would have not thought that we would be in this day and age where we're seeing that kind of movement on products that directly align with our portfolio. That's happening at the FDA level. You're seeing a lot of these initiatives. There's also then at state levels bills to get better coverage for menopause care, get better coverage for products, right? Women don't get the worst first. They get the best, most recently FDA approved treatments as an option. Then you've got institutions like the Milken Institute that have really mobilized their connections, their connections to novel capital, and their policy connections to try to make movement on a variety of fronts. Regulatory, certainly, access to care, funding, investment, really to get more investment in the category.

There's a lot going on at every level, and I feel like Daré is in the center of the circle. We're involved in all of it because we're one of the only companies working so broadly on therapeutics. To really transform healthcare, you have to have all of it, right? You have to have prevention, you have to have access, and you have to have the therapeutics.

Operator

So maybe you can speak to, that is on the policy side and the institutional side, but how about on the strategic side, the pharma side? I mean, they were-

Sabrina Johnson
CEO, Daré Bioscience

Yes.

Operator

-in women's health at some point in the last couple decades, and they all seem to have disappeared, but why has there not been...

Sabrina Johnson
CEO, Daré Bioscience

Now they are all waking up again.

Operator

Are they waking up? Because, I mean, there has not been as much strategic movement as we would have expected. Even now with all the policy changes, you would think there would be much more rapid movement in. What is the noise behind that?

Sabrina Johnson
CEO, Daré Bioscience

Yeah. We are seeing a lot of shift, right? As it happens with pharma, I think things are always in cycles, right? Like what is in and what is out in terms of where they are making their investments, and they have to plan so far ahead, right, in terms of where their therapeutic focus is. There was definitely...

Operator

They do not seem to be planning for that 2030 cliff.

Sabrina Johnson
CEO, Daré Bioscience

Right. No, they are not. The opportunity for Daré existed because they were leaning back when we saw an opportunity to lean in and advance this portfolio. Now what you are seeing is you are seeing companies, and they have been very public about this, like Eli Lilly, right? Again, recognizing, seeing who their customers are for their GLP-1 products and recognizing that there is opportunity there. So the players have shifted, right?

You see some players kind of leaning out, and you see players leaning in. Sun's acquisition of Organon, I mean, they have been very public in saying they want to get more in the branded space, and they see women's health as a real opportunity to kind of lean into the branded space around that. So, I feel like it is what often happens. The chairs are moving, right? We just move the players around, but there remain large players.

They remain the multinational companies, the European companies, Gedeon Richter, Theramex just got announced an acquisition. So, the landscape is there. The pipeline investment has not been there.

Operator

Right.

Sabrina Johnson
CEO, Daré Bioscience

Which is why it's a nice opportunity for us.

Operator

I did notice this potential commercialization independently through this 503B-

Sabrina Johnson
CEO, Daré Bioscience

Yeah.

Operator

-pathway. This is new to me.

Sabrina Johnson
CEO, Daré Bioscience

Yes.

Operator

Maybe you can explain that a little bit, how you can actually commercialize something before it's FDA approved.

Sabrina Johnson
CEO, Daré Bioscience

Yeah. We hear a lot about compounding, especially if you follow like a Hims or a Ro.

That is all compounded. Any of the custom pharmacies that you might see on the telehealth sites, those are custom compounded products. Primarily what is called 503A, which is pharmacy compounding. Pharmacy compounding, it is not like GMP. You just have to have a recipe, and it does not have the same traceability, quality standards as you have. That has always been allowed for quite some time on a named patient basis. In 2012, the FDA, there were new category of compounding that was allowed, which is 503B. It is only for certain circumstances and certain drugs. We just happen to be working on drugs that are on that list. What 503B allows is at an outsourcing facility that is subject to FDA inspection, has to follow normal pharmaceutical GMP, and has to report to the FDA twice a year everything they are doing, everything they are making and distributing.

It allows them for drugs on that list to make them under large-scale, normal GMP standards. Typically, a drug that is going to be made that way does not have data behind it. We do not typically think of a product like ours, where we have run the clinical studies, we have evidence behind what the product does, what someone can expect to experience on the product, to be available that route.

What we found was, we are breaking new ground, as we often are at Daré, in terms of there is nothing FDA approved for arousal in women, so there is no regulatory roadmap. We are working on that roadmap with the FDA. What we found in 2024, there was so much noise about our product. ACOG, the gynecology group, did a podcast about it. They did an editorial about it. We were getting a lot of inbound from healthcare providers and women.

How can I get access to this? It is the only studied formulation that is available that has actually got evidence behind it. How can we get access to it?" It took us a lot of work to figure out how we could do a path there, but I am proud that we figured out a way to get something in the hands of healthcare provider and women that they are asking for and want, while we are still working on an ultimate 505B2 pathway, which is the path that this would get an ultimate approval. We are excited to do it. It has been a journey, something different for us, but I am really happy that we have been able to respond to the demand.

And we opened up, so some of the providers came to us and wanted to start writing prescriptions for it earlier this year, even though it's not available yet, because they want to be a lot of KOLs. They want to be seen as the first and doing the innovative new thing. That's also been great because we can see the demand coming into the system.

Operator

Okay. So, do you see the 503B approach being sort of a backstop or a guarantee, or, I don't know, the right word?

Sabrina Johnson
CEO, Daré Bioscience

It's really a way to give women. We're filling gaps where nothing exists.

And it's a really great way to have our mission align with something that also, from a business perspective, makes a lot of sense, right? We want to get great products into the hands of women where they don't have options, and this is a pathway.

where we can do that and get commercial relationships, right? Build the business for future growth.

Operator

How does that either incentivize or disincentivize the FDA to focus on this product? I mean, because they've been very difficult.

Sabrina Johnson
CEO, Daré Bioscience

It's a different group.

Operator

Yeah.

Sabrina Johnson
CEO, Daré Bioscience

The reality that's like.

Operator

They've not been helpful in that regard.

Sabrina Johnson
CEO, Daré Bioscience

I don't think it changes anything from that perspective.

Operator

How are they viewing it now, like the women's division at FDA? Are they becoming more motivated to...

Sabrina Johnson
CEO, Daré Bioscience

There's a lot of. There's a separate group at the FDA, and has their own kind of associate commissioner that's focused on women's health. It's not one of the review divisions. It's not part of CDER. It's not part of CDRH. It's a separate group at the FDA, but it's specifically tasked on women's health and helping kind of bridge across the organization of how do we move more products forward more quickly. There is definitely effort and engagement. But I always say, it's not like any other therapeutic area. When you don't have a roadmap-

-that work has to be done with the FDA. There's just no way around it. You might have to validate new patient-reported outcomes. There's just extra work to be done.

Operator

I guess in the last few minutes, maybe you can talk about some of the interesting financing arrangements you've had. You've been very unique in raising money.

Sabrina Johnson
CEO, Daré Bioscience

We have been.

Operator

Yeah.

Sabrina Johnson
CEO, Daré Bioscience

I think that's key to unlocking the opportunity that exists here, right? The category exists because it has been underinvested. That means we have to be creative, and we have. The grant funding is foundational, obviously.

Over 75 million in non-dilutive funding. We've also done a Reg A offering, which is a way for anyone to be able to. It's a public offering that anyone can participate in.

Operator

Like almost like a crowdfunding.

Sabrina Johnson
CEO, Daré Bioscience

It is. I mean, you don't have to. The beauty is you don't have. Normally, those are relegated. A public offering is usually only for accredited investors. This is a way for someone who is not an accredited investor to participate. We've done that. And it's wonderful to be able to have our customers and our clinicians who work with us become owners-

Operator

So-

Sabrina Johnson
CEO, Daré Bioscience

in the company.

Operator

-the investors that you've gotten have been the clinicians also?

Sabrina Johnson
CEO, Daré Bioscience

Yeah. There's also, like, there are some investor, like people who would consider themselves truly investors who have participated more significantly.

But yeah, it's a lot of clinicians and women who are really interested in our products.

So, that's been an interesting vehicle. I think again, it's on us to just sort of to be creative. We're sitting on a lot of really disruptive product opportunities in the women's health category, but we have to be eyes wide open. It has been an underfunded category, and you can't change that overnight. Still, only 1% of private healthcare investment goes into products like these that are conditions that solely affect women.

Operator

Do you feel like you have sufficient funding to launch these two products directly-

Sabrina Johnson
CEO, Daré Bioscience

Yeah, we're good on the...

Operator

-and develop.

Sabrina Johnson
CEO, Daré Bioscience

We're good on the launch that we're doing right now. We definitely, we're focusing right now from a development stage, the products that have grant funding supporting them. So, the DARE-HPV product, the Ovaprene product, those are funded with grants. We have our DARE-LARC1, which I didn't really talk about, but it's our implanted product. We've been presenting on it a lot lately because it's a programmable implant that can release over time. We've been getting a lot of interest in that product for other categories like metabolic disorders, obesity, where that kind of interesting control could have utility. But those are grant-funded programs.

Operator

Okay, great. I think that's all the time we have.

Sabrina Johnson
CEO, Daré Bioscience

Awesome.

Operator

Thank you.

Sabrina Johnson
CEO, Daré Bioscience

Great.

Operator

That's great.

Sabrina Johnson
CEO, Daré Bioscience

Thank you all.

Operator

Thank you.